A bstract. Arginine vasopressin (AVP) stimulates ACTH release in man and acts synergistically with synthetic ovine corticotropin-releasing factor (oCRF) in vitro. This study was designed to examine in man the combined effects of synthetic AVP (10 U intramuscularly) and oCRF (1 gg/kg intravenously) on ACTH release.
Introduction
Corticotropin-releasing factor (CRF),' a 41-amino acid peptide isolated from ovine hypothalamic extracts (1, 2) , is a physiologically important mediator of ACTH secretion (3, 4) . In man, ovine CRF (oCRF) is a potent stimulus to ACTH secretion (5) and has a prolonged duration of action (6) that is probably due to its prolonged circulating half-life in plasma (7) .
Vasopressin (VP), which, like CRF, has been localized in cells of the paraventricular nucleus of the hypothalamus (8) , also releases ACTH, albeit with less potency than CRF, from anterior pituitary cells in vitro (1, (9) (10) (11) (12) (13) and in vivo in rats (14) (15) (16) and humans (17) (18) . Although shown to be an ACTH secretagogue, the physiologic role played by VP in the regulation of ACTH secretion is uncertain (3, 19, 20) . Studies in Brattleboro rats, which genetically lack VP but have ACTH-releasing activity in extracts of their hypothalami and secrete ACTH in response to stress, suggest that VP plays only a minor role (21) (22) (23) .
Over the last decade, an hypothesis has emerged that VP may modulate the ACTH response to CRF and may be only one of several factors influencing ACTH secretion (3, 19, 23, 24) . Early studies showed that low doses of VP potentiated the ACTH-releasing activity of hypothalamic extracts in rats (25) . This work has been confirmed in vitro with hypothalamic extracts from Brattleboro rats as the source of CRF (21, 22) and with synthetic oCRF (4, 13, 26) . The mechanism of this synergistic effect may be through potentiation of cyclic AMP accumulation induced by CRF (26) .
Based on this evidence, a role for VP as a physiologic modulator of ACTH secretion should be considered. We designed this study to examine the effect of VP and oCRF, administered singly or in combination, on Hormone assays. Cortisol was measured in unextracted plasma by solid-phase radioimmunoassay (Micromedic Systems, Inc., Horsham, PA). ACTH was measured by radioimmunoassay in unextracted plasma (27) by using antibody IgG-ACTH-I (IgG Corp., Nashville, TN), which is directed at the ACTH-(5-18) sequence. The intraassay coefficients of variation were 7.3 and 4.6% at 15 and 60 pg/ml, respectively (n = 5), and the respective interassay coefficients of variation were 9.2 and 8.6% (n = 5).
Statistical analysis. For the purpose of calculating mean values for the increments in hormone levels, undetectable levels of IR-ACTH (i.e., <10 pg/ml) were assigned a value half that of the detection limit (i.e., 5 pg/ml). All IR-cortisol levels were at or above the limit ofdetectability, which was 1.3 ug/ml. Mean peak responses were compared by analysis of variance and Duncan's multiple range test (28) .
Results
Plasma IR-ACTH levels. Basal plasma IR-ACTH for all subjects was <9±1.2 pg/ml (mean±SE). AVP and oCRF, when given individually, caused rapid rises in plasma IR-ACTH (Fig. 1) to similar mean peak levels of 25±6.6 and 33±4.6 pg/ml, respectively (Fig. 3) . The peak response occurred 15 min after AVP and 15-60 min after oCRF administration. The duration of the IR-ACTH response to oCRF was longer than to AVP; IR-ACTH levels returned to basal level within 75 min after AVP, but remained elevated for up to 4 h after oCRF (Fig. 1) .
When AVP was given 15 min before oCRF, the mean peak IR-ACTH level (85±4.6 pg/ml) was only 2.6 times greater than after oCRF alone (P < 0.01, Fig. 3 ). Compared with oCRF alone, simultaneous administration of AVP and oCRF caused a possibly more rapid rise in plasma IR-ACTH (Fig. 1 ) to a fourfold greater mean peak of 132±11 pg/ml (P < 0.01, Fig.  3 ). Following either combination ofAVP and oCRF, IR-ACTH dropped to levels seen after oCRF alone by 60-90 min and remained elevated for up to 4 h (Fig. 1) 1) to a mean peak of 169±20 pg/ml (Fig. 3 ). This level was 5.1 times greater than after oCRF alone (P < 0.01), but only 1.3 times greater than after simultaneous oCRF and AVP (P < 0.05). The duration of the response also appeared greater than that to oCRF or AVP alone or in combination. Plasma IR-cortisol levels. Basal plasma IR-cortisol for all subjects was 4.9±0.4 ug/dl (mean±SE). AVP alone caused a brief rise in IR-cortisol to 16.5±0.9 /Ag/dl at 30 min, followed by a rapid decline to base-line level by 180 min (Figs. 2 and  3 ). oCRF stimulated a similar rise in plasma IR-cortisol to a mean peak of 16.4±2.3 ,ug/dl (Fig. 3) , but the level peaked later and remained elevated for at least 4 h (Fig. 2) . After simultaneous AVP and oCRF, the mean peak IR-cortisol was 22.8±2.1 lug/ dl, 1.4 times greater than after AVP or oCRF alone (P < 0.05, 3 ). When AVP was injected 15 min before oCRF, the combination resulted in an intermediate mean peak IR-cortisol of 18.5±0.8 ug/dl, which was significantly less (P < 0.05) than that after simultaneous administration, and did not differ significantly from that after either AVP or oCRF alone (Fig. 3) . In all three studies in which oCRF was given, IR-cortisol remained elevated for at least 4 h (Fig. 2) . The mean peak IRcortisol concentration after insulin-induced hypoglycemia was 26 .1±3.8 ,g/dl (Fig. 3) , which was slightly but not significantly greater than that after simultaneous AVP and oCRF administration; the levels also remained slightly higher for the duration of the experiment (Fig. 2) .
Signs and symptoms. All subjects who received AVP alone or in combination with oCRF demonstrated a marked facial pallor, but had no symptoms or changes in blood pressure or 
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Vasopressin Potentiates Corticotropin-releasing Factor pulse rate. Symptoms experienced by subjects receiving oCRF alone were absent or minimal and consisted, when present, only of mild facial flushing and transient dyspnea. There was no difference in symptoms when AVP was given simultaneously with or 15 min before oCRF. Analysis of blood cell counts, serum chemistry profiles, and urinalyses of the subjects on the day following each experiment showed no consistent changes from base-line values.
Discussion
In this study, we have compared the plasma IR-ACTH and IRcortisol response in man to AVP and oCRF, given alone and in combination. When these hormones were given individually in similar doses (oCRF, 14.8-19.5 nmol, mean 16.5 nmol; AVP, 10 pressor units, or 23 nmol), they caused similar rates of rise and mean peak levels of plasma IR-ACTH and IR-cortisol. In contrast, the ACTH-releasing potency of oCRF has been found to be 5-10 times greater than that of AVP on a molar basis in rat anterior pituitary cells (1) and in intact rats (29) . This discrepancy could be due to different routes of administration, species differences in rates of metabolism, or species differences in pituitary responsiveness to these hormones. Another explanation is that AVP might cause release of endogenous CRF in addition to having a direct action on the pituitary (30) . The subjects in the present study had no signs or symptoms of stress after AVP injection, so a nonspecific stress response appears to be an unlikely explanation for their IR-ACTH and IR-cortisol responses to AVP.
Simultaneous administration of AVP and oCRF caused a synergistic effect on ACTH secretion, resulting in a fourfold greater plasma IR-ACTH response than after either agent alone.
This response is similar to that described in intact rats (25) and rat anterior pituitary cells (4, 13, 26) , and adds further support to the hypothesis that AVP is an important physiologic modulator of ACTH secretion.
Maximum ACTH secretion occurred when AVP and oCRF were administered simultaneously. When oCRF was given 15 min after AVP, which is the time of maximum plasma IR-ACTH response to AVP, the plasma IR-ACTH peak was reduced to only 2.6 times the response to oCRF alone. Thus, it appears that the corticotroph must be exposed to both agents simultaneously to produce a maximal synergistic effect. The mechanism of this synergistic effect may be related to potentiation by AVP of intracellular cAMP levels stimulated by oCRF (26) , but it is not clear why a synergistic rather than an additive effect is observed.
In the experiments in which oCRF was administered, IR-ACTH levels remained elevated for at least 4 h. In contrast, the effect of AVP was brief, with IR-ACTH returning to base line within 75 min. This prolonged effect of oCRF has been noted before (6) and is probably due to its slow metabolic clearance (7) .
For comparison, another potent stimulus to ACTH secretion, insulin-induced hypoglycemia, was studied. The peak IR-ACTH level following insulin was 1.3 times greater and of longer duration than that observed after simultaneous administration of AVP and oCRF. This finding could reflect the fact that the pituitary was exposed to less than maximally stimulating concentrations ofoCRF and/or AVP or that the duration ofexposure was less. Doses of oCRF up to 30 times greater than those used in this study cause still higher plasma IR-ACTH responses (5). Alternatively, hypoglycemia might cause the release ofadditional ACTH secretogogues, whose combined effect might be greater than that of oCRF and AVP.
The IR-cortisol response to these agents reflected the peak IR-ACTH responses, although the differences were not as marked. AVP, oCRF, and AVP given 15 min before oCRF caused similar peak plasma IR-cortisol levels, whereas simultaneous AVP and oCRF caused a 1.4-fold greater IR-cortisol level. Insulin-induced hypoglycemia produced a still greater response. The cortisol response to these agents was not directly proportional to the IR-ACTH response, indicating that plasma ACTH levels of only 25-50 pg/ml produce near maximal, acute stimulation of adrenal steroidogenesis.
The sequence for human CRF has recently been deduced from the nucleotide sequence ofthe gene (31) . It differs in seven amino acid residues from oCRF, but is identical to rat CRF (32) . Until synthetic oCRF and synthetic human CRF are tested in man, one cannot assume that their activities are identical.
In conclusion, the ACTH response to oCRF in man is potentiated by AVP, suggesting a physiologic role for AVP as a modulator of ACTH secretion.
